A randomized controlled trial of atomoxetine in generalized social anxiety disorder / Lakshmi N. Ravindran en Journal of Clinical Psychopharmacology, Año 2009 - Vol. 29 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2009 - Vol. 29 - No. 6 (Diciembre) . - pp. 561-564 Título : A randomized controlled trial of atomoxetine in generalized social anxiety disorder Tipo de documento: texto impreso Autores: Lakshmi N. Ravindran, Autor ; Daniel S. Kim, Autor ; Andrea M. Letamendi, Autor Fecha de publicación: 2022 Artículo en la página: pp. 561-564 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Atomoxetina, Trastorno de ansiedad social, Fobia social, Farmacoterapia Resumen: The current mainstays of social anxiety disorder pharmacotherapy are serotonergic agents, with less known about the efficacy of more noradrenergic drugs. Atomoxetine (ATM), a highly selective norepinephrine reuptake inhibitor, is currently approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). Link: ./index.php?lvl=notice_display&id=29480 [artículo] A randomized controlled trial of atomoxetine in generalized social anxiety disorder [texto impreso] / Lakshmi N. Ravindran, Autor ; Daniel S. Kim, Autor ; Andrea M. Letamendi, Autor . - 2022 . - pp. 561-564. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2009 - Vol. 29 - No. 6 (Diciembre) . - pp. 561-564 Palabras clave: Atomoxetina, Trastorno de ansiedad social, Fobia social, Farmacoterapia Resumen: The current mainstays of social anxiety disorder pharmacotherapy are serotonergic agents, with less known about the efficacy of more noradrenergic drugs. Atomoxetine (ATM), a highly selective norepinephrine reuptake inhibitor, is currently approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). Link: ./index.php?lvl=notice_display&id=29480

---

1 (1 - 1 / 1)